Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HRAS | P01112 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075972 | 0.91 | CYP1A2 (0.37) | ACSS2TPSAB1TPSD1TPSG1BRD4 | |
| SCHEMBL7071857 | 0.87 | ACSS2 (0.39) | ITGB3ITGA2BACSS2TPSAB1TPSD1 | |
| SCHEMBL7073370 | 0.86 | TPSAB1 (0.42) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL7073556 | 0.86 | TPSAB1 (0.39) | ACSS2TPSAB1TPSD1TPSG1 | |
| SCHEMBL7067665 | 0.85 | TPSAB1 (0.36) | ACSS2TPSAB1TPSD1TPSG1 | |
| SCHEMBL7070345 | 0.85 | TRPV1 (0.37) | ACSS2 | |
| SCHEMBL7072025 | 0.84 | TPSAB1 (0.36) | ACSS2TPSAB1TPSD1TPSG1 | |
| SCHEMBL7075123 | 0.84 | PDE4A (0.42) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL7072722 | 0.84 | MAPT (0.38) | ACSS2TPSAB1TPSD1TPSG1 | |
| SCHEMBL7069773 | 0.84 | F10 (0.41) | TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | ITGB3 1846/4885ITGA2B 2582/4885ACSS2 609/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | ITGB3 1351/4885ITGA2B 2552/4885ACSS2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.